Patents by Inventor Mark S. Stanley

Mark S. Stanley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridyl inhibitors of hedgehog signalling
    Patent number: 9790183
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: October 17, 2017
    Assignee: GENENTECH, INC.
    Inventors: Janet L. Gunzner-Toste, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • Pyridyl inhibitors of hedgehog signalling
    Patent number: 9321761
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: April 26, 2016
    Assignees: CURIS, INC., GENENTECH, INC.
    Inventors: Janet L. Gunzner-Toste, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. LaLonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • Pyridyl inhibitors of hedgehog signalling
    Patent number: 9278961
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 8, 2016
    Assignees: GENENTECH, INC., CURIS, INC.
    Inventors: Janet L. Gunzner, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F. T. Koehler
  • Janus kinase inhibitor compounds and methods
    Patent number: 8486950
    Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereof.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: July 16, 2013
    Assignee: F. Hoffmann-La Roche AG
    Inventors: Simon Charles Goodacre, Yingjie Lai, Jun Liang, Steven R. Magnuson, Kirk D. Robarge, Mark S. Stanley, Vickie Hsiao-Wei Tsui, Karen Williams, Birong Zhang, Aihe Zhou
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20120094980
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: October 14, 2011
    Publication date: April 19, 2012
    Inventors: Janet L. Gunzner, Daniel P. Sutherlin, Mark S. Stanley, Liang Bao, Georgette Castanedo, Rebecca Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina, Michael F.T. Koehler
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20110092461
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: December 6, 2010
    Publication date: April 21, 2011
    Inventors: Janet L. GUNZNER, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • Aza-benzothiophenyl compounds and methods of use
    Patent number: 7893085
    Abstract: The invention relates to azabenzothiophenyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azabenzothiophenyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: February 22, 2011
    Assignee: Genentech, Inc
    Inventors: Pascal Pierre Savy, Stephen Price, Hazel Joan Dyke, John Gary Montana, Karen Williams, Mark S. Stanley, Liang Bao
  • Pyridyl inhibitors of hedgehog signalling
    Patent number: 7888364
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Grant
    Filed: September 2, 2005
    Date of Patent: February 15, 2011
    Assignee: Curis, Inc.
    Inventors: Janet L. Gunzner, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • Aza-indolyl compounds and methods of use
    Patent number: 7855216
    Abstract: The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: December 21, 2010
    Assignee: Genentech, Inc.
    Inventors: Simon Charles Goodacre, Karen Williams, Stephen Price, Hazel Joan Dyke, John Gary Montana, Mark S. Stanley, Liang Bao, Wendy Lee
  • PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING
    Publication number: 20090281089
    Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.
    Type: Application
    Filed: April 8, 2009
    Publication date: November 12, 2009
    Applicant: Genentech, Inc.
    Inventors: Janet L. Gunzner, Daniel P. Sutherlin, Mark S. Stanley, Liang Bao, Georgette Castanedo, Rebecca L. LaLonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
  • AZA-INDOLYL COMPOUNDS AND METHODS OF USE
    Publication number: 20080242655
    Abstract: The invention relates to azaindolyl compounds of Formula I with anti-cancer and/or anti-inflammatory activity and more specifically to azaindolyl compounds which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.
    Type: Application
    Filed: November 29, 2007
    Publication date: October 2, 2008
    Inventors: Simon Charles Goodacre, Karen Williams, Stephen Price, Hazel Joan Dyke, John Gary Montana, Mark S. Stanley, Liang Bao, Wendy Lee
  • Integrin receptor inhibitors
    Patent number: 7265146
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to ?4 integrin receptors and thereby inhibit binding of ligands for ?4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with ?4 integrins or their ligands.
    Type: Grant
    Filed: April 20, 2005
    Date of Patent: September 4, 2007
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Patent number: 7094869
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: August 22, 2006
    Assignee: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson
  • Integrin receptor inhibitors
    Patent number: 6933314
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to ?4 integrin receptors and thereby inhibit binding of ligands for ?4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with ?4 integrins or their ligands.
    Type: Grant
    Filed: September 30, 2003
    Date of Patent: August 23, 2005
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • LFA-1 antagonist compounds
    Patent number: 6872735
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: March 29, 2005
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Integrin receptor inhibitors
    Publication number: 20040077693
    Abstract: Provided are compounds of formula (I) 1
    Type: Application
    Filed: September 30, 2003
    Publication date: April 22, 2004
    Applicant: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • LFA-1 antagonist compounds
    Publication number: 20040058968
    Abstract: The invention relates to novel compounds having formula (I) 1
    Type: Application
    Filed: July 11, 2003
    Publication date: March 25, 2004
    Applicant: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Integrin receptor inhibitors
    Patent number: 6706753
    Abstract: Provided are compounds of formula (I) wherein A, Q, W, X, Y, Z, R1 to R4, m and n are as defined herein. Compounds of the invention bind to &agr;4 integrin receptors and thereby inhibit binding of ligands for &agr;4 integrins which is useful for prophylactic and/or therapeutic treatment of diseases and conditions associated with &agr;4 integrins or their ligands.
    Type: Grant
    Filed: December 6, 2002
    Date of Patent: March 16, 2004
    Assignee: Genentech, Inc.
    Inventors: Dean R. Artis, David Y. Jackson, Thomas E. Rawson, Mark E. Reynolds, Daniel P. Sutherlin, Mark S. Stanley
  • LFA-1 antagonist compounds
    Patent number: 6667318
    Abstract: The invention relates to novel compounds having formula (I) wherein Cy, X, Y, L and R1-6 are as defined herein. The compounds bind CD11/CD18 adhesion receptors such as Lymphocyte Function-associated Antigen-1 (LFA-1) and are therefore useful for treating disorders mediated by LFA-1 such as inflammation and autoimmune diseases.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: December 23, 2003
    Assignee: Genentech, Inc.
    Inventors: Daniel J. Burdick, Mark S. Stanley, David Oare, Mark E. Reynolds, Thomas R. Gadek, James C. Marsters
  • Low molecular weight peptidomimetic growth hormone secretagogues
    Publication number: 20030139348
    Abstract: The present invention comprises growth hormone releasing peptides/peptidomimetics (GHRP) capable of causing release of growth hormone from the pituitary. Compositions containing the GHRP's of this invention are used to promote growth in mammals either alone or in combination with other growth promoting compounds, especially IGF-1. In a method of this invention GHRP's in combination with IGF-1 are used to treat Type II diabetes. An exemplary compound of this invention is provided below.
    Type: Application
    Filed: August 19, 2002
    Publication date: July 24, 2003
    Applicant: Genentech, Inc.
    Inventors: Todd C. Somers, Kathleen A. Elias, Ross G. Clark, Robert S. McDowell, Mark S. Stanley, John P. Burnier, Thomas E. Rawson